The 5q-syndrome: Biology and treatment

Current Treatment Options in Oncology

Volumn 12, Issue 4, 2011, Pages 354-368

  Padron, Eric ^a   Komrokji, Rami ^a   List, Alan F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ARRAY 614; CANERSEN; ERYTHROPOIETIN; LENALIDOMIDE; MICRORNA; MICRORNA 145; MICRORNA 146; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MLN 4294; PLACEBO; PROTEIN INHIBITOR; PROTEIN P53; THALIDOMIDE; UNCLASSIFIED DRUG;

5Q- SYNDROME; ALLELE; ARTICLE; BONE MARROW SUPPRESSION; CDC25C GENE; CTNNA1 GENE; DIAPH1 GENE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EGR1 GENE; GENE; GENE DELETION; GENE EXPRESSION; GENE INTERACTION; GENE MAPPING; GENE MUTATION; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PHENOTYPE; PP2ACALPHA GENE; RNA INTERFERENCE; RPS14 GENE; SPARC GENE; THROMBOCYTOPENIA; TP53 GENE; TREATMENT RESPONSE;

ANEMIA, MACROCYTIC; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; HUMANS; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 84855907171     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0165-1     Document Type: Article

References (76)

1. Van Den Berghe H, Cassiman J-J, David G, Fryns J-P, Michaux J-L, Sokal G. Distinct haematological disorder with deletion of long arm of No. 5 chromosome. Nature. 1974;251:437-8.
2. Nimer SD, Golde DW. The 5q- abnormality. Blood. 1987;70:1705-12.
3. Mohamedali A, Mufti GJ. Van-den Berghe's 5q- syndrome in 2008. Br J Haematol. 2009;144:157-68.
4. Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol. 2006;24:2576-82. (Pubitemid 46630637)
5. Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes: Current status and future directions. Hematol Oncol Clin North Am. 2010;24:377-88.
6. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-57. (Pubitemid 40204668)
7. Kantarjian H, O'Brien S, Ravandi F, et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: How does it relate to the original lenalidomide experience in MDS? Cancer. 2009;115:5202-9.
8. Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1- 1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A. 1997;94:6948-53. (Pubitemid 27281971)
9. Jaju RJ, Boultwood J, Oliver FJ, et al. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer. 1998;22:251-6. (Pubitemid 28262202)
10. Le Beau MM, Espinosa 3rd R, Neuman WL, et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A. 1993;90:5484-8. (Pubitemid 23176185)
11. Boultwood J, Fidler C, Lewis S, et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: Delineation of the critical region on 5q and identification of a 5qbreakpoint. Genomics. 1994;19:425-32. (Pubitemid 24071315)
12. Willman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science. 1993;259:968-71. (Pubitemid 23080665)
13. Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002;99:4638-41. (Pubitemid 34627240)
14. Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol. 2007;139:578-89. (Pubitemid 350043812)
15. Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia. 2010;24:756-64.
16. Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007;13:78-83. (Pubitemid 46067389)
17. Pellagatti A, Cazzola M, Giagounidis AA, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: Involvement of interferon- stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006;108:337-45. (Pubitemid 43990647)
18. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451:335-9.
19. Nakamichi NN, Kao FT, Wasmuth J, Roufa DJ. Ribosomal protein gene sequences map to human chromosomes 5, 8, and 17. Somat Cell Mol Genet. 1986;12:225-36. (Pubitemid 16040670)
20. Rhoads DD, Dixit A, Roufa DJ. Primary structure of human ribosomal protein S14 and the gene that encodes it. Mol Cell Biol. 1986;6:2774-83.
21. Dana S, Wasmuth JJ. Linkage of the leuS, emtB, and chr genes on chromosome 5 in humans and expression of human genes encoding protein synthetic components in human-Chinese hamster hybrids. Somatic Cell Genet. 1982;8:245-64. (Pubitemid 12095609)
22. Narla A, Ebert BL. Ribosomopathies: Human disorders of ribosome dysfunction. Blood. 2010;115:3196-205.
23. Craven SE, French D, Ye W, de Sauvage F, Rosenthal A. Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome. Blood. 2005;105:3528-34. (Pubitemid 40628195)
24. McGowan KA, Li JZ, Park CY, et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet. 2008;40:963-70.
25. Heise C, Carter T, Schafer P, Chopra R. Pleiotropic mechanisms of action of lenalidomide efficacy in del (5q) myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010;10:1663-72.
26. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237-45.
27. Ferreira-Cerca S, Hurt E. Cell biology: Arrest by ribosome. Nature. 2009;459:46-7.
28. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010;16:59-66. This manuscript successfully crossed a powerful mouse model of the 5q- syndrome with a p-53 deficient mouse strain. This cross resulted in restoration of the hematopoetic progenitor defects seen in the 5q- model suggesting a critical P53 dependent mechanism.
29. Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29:1971-9.
30. Starczynowski DT, Karsan A. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle. 2010;9:855-6.
31. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010;16:49-58. This mansucript identified two miRs expressed within the common deleted region and their targets. They further showed that knocking these miRs down resulted in the partial recapitulation of the 5q- syndrome phenotype in a murine model.
32. DeWard AD, Leali K, West RA, Prendergast GC, Alberts AS. Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous- related Formin mDia1 knockout mice. PLoS One. 2009;4:e7102.
33. Eisenmann KM, Dykema KJ, Matheson SF, et al. 5qmyelodysplastic syndromes: Chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene. 2009;28:3429-41.
34. Peng J, Kitchen SM, West RA, Sigler R, Eisenmann KM, Alberts AS. Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1. Cancer Res. 2007;67:7565-71. (Pubitemid 47287487)
35. Huang RP, Fan Y, de Belle I, et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer. 1997;72:102-9. (Pubitemid 27314646)
36. Sukhatme VP, Cao XM, Chang LC, et al. A zinc fingerencoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell. 1988;53:37-43.
37. Lemaire P, Revelant O, Bravo R, Charnay P. Two mouse genes encoding potential transcription factors with identical DNA-binding domains are activated by growth factors in cultured cells. Proc Natl Acad Sci U S A. 1988;85:4691-5.
38. Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. Proc Natl Acad SciU S A. 1996;93:11831-6. (Pubitemid 26347209)
39. Liu C, Yao J, de Belle I, Huang RP, Adamson E, Mercola D. The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1. J Biol Chem. 1999;274:4400-11.
40. Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D. Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J Biol Chem. 2003;278:11802-10. (Pubitemid 36800149)
41. Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007;110:719-26. (Pubitemid 47105411)
42. Swaroop A, Hogan BL, Francke U. Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: Sequence, expression, and localization of the gene to chromosome 5q31-q33. Genomics. 1988;2:37-47.
43. Goldblum SE, Ding X, Funk SE, Sage EH. SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. Proc Natl Acad Sci U S A. 1994;91:3448-52. (Pubitemid 24130254)
44. Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007;104:11406-11. (Pubitemid 47175153)
45. Zhang L-H, Schafer PH, Muller G, Stirling D, Bartlett B. Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-hodgkin lymphoma cells are associated with increased SPARC expression. Blood (ASH Annual Meeting Abstracts) 2008;112:2612
46. Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q- syndrome: Thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007;21:1931-6. (Pubitemid 47299966)
47. Fidler C, Strickson A, Boultwood J, Waincoat JS. Mutation analysis of the SPARC gene in the 5q-syndrome. Am J Hematol. 2000;64:324. (Pubitemid 30622247)
48. Pokutta S, Weis WI. Structure of the dimerization and beta-catenin-binding region of alpha-catenin. Mol Cell. 2000;5:533-43.
49. Vasioukhin V, Bauer C, Degenstein L, Wise B, Fuchs E. Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell. 2001;104:605-17. (Pubitemid 32201954)
50. Shibata H, Takano H, Ito M, et al. Alpha-catenin is essential in intestinal adenoma formation. Proc Natl Acad Sci U S A. 2007;104:18199-204. (Pubitemid 350210844)
51. Gil-Bernabe AM, Romero F, Limon-Mortes MC, Tortolero M. Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase. Mol Cell Biol. 2006;26:4017-27. (Pubitemid 43788006)
52. Jones TA, Barker HM, da Cruz e Silva EF, et al. Localization of the genes encoding the catalytic subunits of protein phosphatase 2A to human chromosome bands 5q23-9q31 and 8p12-9p11.2, respectively. Cytogenet Cell Genet 1993;63:35-41. (Pubitemid 23102319)
53. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A 2009;106:12974-9. This manuscript identifies a link between the common deleted region and sensitivity to lenalidomide in low risk MDS with a del(5q) abnormality.
54. Sartor H, Ehlert F, Grzeschik KH, Muller R, Adolph S. Assignment of two human cell cycle genes, CDC25C and CCNB1, to 5q31 and 5q12, respectively. Genomics. 1992;13:911-2.
55. Strausfeld U, Labbe JC, Fesquet D, et al. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature. 1991;351:242-5. (Pubitemid 21896574)
56. Gould KL, Moreno S, Tonks NK, Nurse P. Complementation of the mitotic activator, p80cdc25, by a human protein-tyrosine phosphatase. Science. 1990;250:1573-6. (Pubitemid 120034370)
57. Bulavin DV, Higashimoto Y, Popoff IJ, et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature. 2001;411:102-7. (Pubitemid 32428198)
58. Ebert BL. Deletion 5q in myelodysplastic syndrome: A paradigm for the study of hemizygous deletions in cancer. Leukemia. 2009;23:1252-6.
59. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-6.
60. List AF, Baker AF, Green S, Bellamy W. Lenalidomide: Targeted anemia therapy for myelodysplastic syndromes. Cancer Control. 2006;13(Suppl):4-11. (Pubitemid 46148104)
61. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-65. (Pubitemid 44511560)
62. List A, Wride K, Knight R. Transfusion burden, disease duration and age identify non-deletion 5q MDS patients highly responsive to lenalidomide treatment. European Hematology Association, 13th congress 2008.
63. Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26:5943-9.
64. Fenaux P, Giagounidis A, Selleslag DL, et al. Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality. J Clin Oncol (Meeting Abstracts) 2010;28:6598
65. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011. This is a large phase 3 clinical trial preformed in Europe confirming the superior efficacy and acceptable safety of lenalidomide in low-risk transfusion dependent MDS patients with a del(5q) abnormality.
66. Ades L, Lebras F, Sebert M, et al. Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM). ASH Annual Meeting Abstracts 2010;116:976
67. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-22. (Pubitemid 38525287)
68. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380-6. (Pubitemid 29295864)
69. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69:7347-56.
70. Muller GW, Chen R,Huang SY, et al. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett. 1999;9:1625-30. (Pubitemid 29274209)
71. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67:746-55. (Pubitemid 46192215)
72. List AF, Rocha K, Zhang L, et al. Secondary Resistance to Lenalidomide in Del(5q) MDS Is Associated with CDC25C & PP2A Overexpression. ASH Annual Meeting Abstracts 2009;114:292
73. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010;363:1025-37. Lenalidomide responding patients with the 5q- syndrome are not cured from their disease. Relapse is nearly universal after some time. This manuscript provides biological evidence of this by showing that, even in responding patient, there exists a lenalidomide non-responsive stem cell compartment.
74. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38(MAPK): Stress responses from molecular mechanisms to therapeutics. Trends Mol Med. 2009;15:369-79.
75. Musto P, Maurillo L, Spagnoli A, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: A retrospective study of 74 patients enrolled in an Italian named patient program. Cancer. 2010;116:1485-94.
76. Zhang Y, Lu H. Signaling to p53: Ribosomal proteins find their way. Cancer Cell. 2009;16:369-77.